CRP and inflammatory bowel disease: 52 patients with IBD double switched (39 CD and 13 UC)18  • Majority of patients in clinical remission (94%) at week 24 following the second switch • 86% remained on infliximab therapy following double switch • No difference in clinical remission, infliximab discontinuation, and adverse events in single vs double switched patients. Single switch (57 CD and 30 UC) compared to double switch (95 CD and 4 UC)17  • No significant difference in clinical disease scores or CRP in patients singly switched vs double switched